Zero Candida Secures South African Patent for ZC-01 Device
Zero Candida (the "Company" or "ZC") (TSXV: ZCT), an Israeli FemTech medical device start-up, is thrilled to announce that it has successfully received a final patent from South Africa. This advancement is marked by the PCT patent PCT-IL 2023050243. The company’s ambition doesn't end here, as it is actively pursuing a global patent portfolio, with applications filed in numerous countries, including the United States, Brazil, and various European nations.
Revolutionizing Women’s Health with Cutting-Edge Technology
The innovative ZC device is an AI-powered tampon-like tool designed to effectively treat Candida fungus with an impressive success rate of 99.999%. This device addresses Vulvo-Vaginal Candidiasis ("VVC"), which impacts about 75% of women worldwide. By utilizing a controlled "Blue Light" technology, Zero Candida’s device aims to eliminate vaginal fungus quickly and without side effects, marking a significant step forward in the FemTech industry.
Enhancing Accessibility to Women's Health Solutions
Zero Candida is committed to bringing technology that allows for hybrid medical services, particularly targeting populations that have historically lacked access to effective treatments, especially in developing countries. The ZC device can capture and transmit treatment data directly to physicians in real-time for personalized assessments, thus improving the quality of care. Thanks to seamless Wi-Fi connectivity, physicians can offer remote consultations, enhancing patient convenience.
Quotes from Leadership
Eli Ben Haroosh, Founder & CEO, expressed, "Zero Candida is revolutionizing women’s healthcare. Our goal is to secure patents across every continent. With a top-tier medical team and international patents, we are positioning ourselves for sustainable success."
Dr. Asher Holzer, CTO & Director, emphasizes the significance of this patent acquisition, stating, "As chief scientist, it’s crucial for us to protect our innovations. Zero Candida is at the forefront of hybrid medicine and technology-driven diagnostics."
The Science Behind the Device
The ZC device stands out with its therapeutic light source that targets the Candida fungus, providing effective and safe treatment. VVC affects a staggering 138 million women annually, with projections indicating that 492 million women will experience it at some point in their lives. Many existing treatments are becoming ineffective as cases of recurrent VVC grow due to drug resistance, thus highlighting the critical need for innovative approaches.
The company has made strides in its research, having signed pre-clinical agreements with hospitals in Israel and Europe and successfully completing safety trials for large animals. The development process is ongoing as the company prepares for clinical trials aimed for implementation in the near future.
Unearthing Future Opportunities
As Zero Candida progresses, it aims not only to improve treatment for current patients but also to widen access to quality medical solutions for underserved communities globally. This approach to women's health integrates both advanced technology and compassionate care, ensuring all women have access to effective treatments.
Conclusion: A New Era in FemTech
Zero Candida's ZC-01 device is anticipated to bring significant advancements in the field of gynecology. Through the development of hybrid medicine and diagnostic technologies, the company is poised to make a lasting impact in women's health. By combining technology with medical expertise, Zero Candida is pioneering a new era in FemTech that prioritizes patient safety and efficacy, setting benchmarks for future innovations.
Frequently Asked Questions
What is the ZC-01 device?
The ZC-01 device is an AI smart tampon-like medical device designed to effectively treat Vulvo-Vaginal Candidiasis (VVC) using therapeutic blue light technology.
How does the device work?
The device uses a controlled light wavelength to target and eliminate Candida fungus safely and effectively, providing a non-chemical treatment solution.
What are the benefits of this device?
The device offers rapid treatment without side effects, personalized care through data sharing with physicians, and aims to broaden access to healthcare solutions for women.
Where is the patent for the ZC-01 device secured?
The ZC-01 device has secured a patent in South Africa, with the intention of expanding its patent portfolio globally.
What future plans does Zero Candida have?
Zero Candida plans to expand its patent applications around the world and is currently preparing for clinical trials to evaluate its device for human use.
